Table 4.
Source of cost | Study year | Study setting | Amount (NPR) | Amount (US dollar) | Reference |
---|---|---|---|---|---|
Average cost per prescription | 2006 | Sample frame: outpatient pharmacy (OPP); Urban setting Sample: 182 DMT2 patients Study design: cross sectional |
1156.2 | 16.2 | (39) |
Total cost per visit | 2010 | Sample frame: A public hospital, a private hospital and two polyclinics one each in Kathmandu and Lalitpur Sample: 227 DMT2 patients Study design: cross sectional |
NR | Mean cost per patient per visit Public sector: Mean 5.1, SD 253, 95% CI 4.3–5.9 Private sector: Mean 17.5, SD 948.2, CI 15.4–9.6 |
(47) |
Total cost per month | 2010 | Sample frame: A public hospital, a private hospital and two polyclinics one each in Kathmandu and Lalitpur Sample: 227 DMT2 patients Study design: cross sectional |
NR | Mean cost of illness per patient per month Mean 40.4, SD 2232.7, 95% CI 36.4–44.5 |
(47) |
Total cost per annum | 2010 | Sample frame: a public hospital, a private hospital and two polyclinics one each in Kathmandu and Lalitpur Sample: 227 DMT2 patients Study design: cross sectional |
NR | Mean cost per patient per annum Mean 445.9, SD 27534.9, 95% CI 396.1–495.6 |
(47) |
Total cost per annum | 2002–2003 | Sample frame: Two sites in Dhulikhel community and Kathmandu's Diabetes clinic; rural and urban setting Sample: 60 DMT2 patients Study design: Prospective observational follow-up |
Cost to the health system and the patient per annum 5470 | NR | (33) |
NR=Not Reported.